Trade Thermo Fisher Scientific - TMO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.64 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Thermo Fisher Scientific Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 499.34 |
Open* | 501.22 |
1-Year Change* | -4.03% |
Day's Range* | 496.13 - 502.88 |
52 wk Range | 475.77-609.85 |
Average Volume (10 days) | 1.07M |
Average Volume (3 months) | 30.20M |
Market Cap | 205.19B |
P/E Ratio | 36.33 |
Shares Outstanding | 385.95M |
Revenue | 43.52B |
EPS | 14.64 |
Dividend (Yield %) | 0.26333 |
Beta | 0.78 |
Next Earnings Date | Oct 24, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 3, 2023 | 499.34 | 9.05 | 1.85% | 490.29 | 502.36 | 490.29 |
Oct 2, 2023 | 495.41 | -7.58 | -1.51% | 502.99 | 503.14 | 490.51 |
Sep 29, 2023 | 506.09 | -1.38 | -0.27% | 507.47 | 509.23 | 504.17 |
Sep 28, 2023 | 502.84 | 6.29 | 1.27% | 496.55 | 506.74 | 496.55 |
Sep 27, 2023 | 498.09 | -3.46 | -0.69% | 501.55 | 503.54 | 494.62 |
Sep 26, 2023 | 501.29 | -0.95 | -0.19% | 502.24 | 505.54 | 500.77 |
Sep 25, 2023 | 505.44 | 5.40 | 1.08% | 500.04 | 505.93 | 499.04 |
Sep 22, 2023 | 502.21 | -0.04 | -0.01% | 502.25 | 506.76 | 500.09 |
Sep 21, 2023 | 501.16 | 0.38 | 0.08% | 500.78 | 503.57 | 498.76 |
Sep 20, 2023 | 504.52 | -4.55 | -0.89% | 509.07 | 511.20 | 503.15 |
Sep 19, 2023 | 508.33 | 5.92 | 1.18% | 502.41 | 509.20 | 502.40 |
Sep 18, 2023 | 507.43 | -5.23 | -1.02% | 512.66 | 513.62 | 506.60 |
Sep 15, 2023 | 515.08 | 0.13 | 0.03% | 514.95 | 533.54 | 508.70 |
Sep 14, 2023 | 515.46 | 2.90 | 0.57% | 512.56 | 517.80 | 504.95 |
Sep 13, 2023 | 510.59 | 11.45 | 2.29% | 499.14 | 525.84 | 497.06 |
Sep 12, 2023 | 510.70 | -3.20 | -0.62% | 513.90 | 513.92 | 509.00 |
Sep 11, 2023 | 514.53 | -0.68 | -0.13% | 515.21 | 517.43 | 510.69 |
Sep 8, 2023 | 517.84 | -8.82 | -1.67% | 526.66 | 531.89 | 512.43 |
Sep 7, 2023 | 531.19 | -2.79 | -0.52% | 533.98 | 537.66 | 530.33 |
Sep 6, 2023 | 536.31 | -3.98 | -0.74% | 540.29 | 543.30 | 535.43 |
Thermo Fisher Scientific Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, October 24, 2023 | ||
Time (UTC) 12:30 | Country US
| Event Q3 2023 Thermo Fisher Scientific Inc Earnings Release Q3 2023 Thermo Fisher Scientific Inc Earnings ReleaseForecast -Previous - |
Tuesday, January 30, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Thermo Fisher Scientific Inc Earnings Release Q4 2023 Thermo Fisher Scientific Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 44915 | 39211 | 32218 | 25542 | 24358 |
Revenue | 44915 | 39211 | 32218 | 25542 | 24358 |
Cost of Revenue, Total | 25944 | 19573 | 16231 | 14213 | 13499 |
Gross Profit | 18971 | 19638 | 15987 | 11329 | 10859 |
Total Operating Expense | 36548 | 29950 | 24424 | 21132 | 20575 |
Selling/General/Admin. Expenses, Total | 8934 | 7816 | 6940 | 6082 | 6028 |
Research & Development | 1471 | 1406 | 1181 | 1003 | 967 |
Unusual Expense (Income) | 140 | 1108 | 89 | -167 | 79 |
Operating Income | 8367 | 9261 | 7794 | 4410 | 3783 |
Interest Income (Expense), Net Non-Operating | -548 | -427 | -569 | -408 | -528 |
Other, Net | 16 | 7 | 68 | 7 | |
Net Income Before Taxes | 7835 | 8841 | 7225 | 4070 | 3262 |
Net Income After Taxes | 7132 | 7732 | 6375 | 3704 | 3055 |
Net Income Before Extra. Items | 6950 | 7725 | 6375 | 3704 | 3055 |
Total Extraordinary Items | 0 | -8 | -117 | ||
Net Income | 6950 | 7725 | 6375 | 3696 | 2938 |
Income Available to Common Excl. Extra. Items | 6950 | 7725 | 6375 | 3704 | 3055 |
Income Available to Common Incl. Extra. Items | 6950 | 7725 | 6375 | 3696 | 2938 |
Diluted Net Income | 6950 | 7725 | 6375 | 3696 | 2938 |
Diluted Weighted Average Shares | 394 | 397 | 399 | 403 | 406 |
Diluted EPS Excluding Extraordinary Items | 17.6396 | 19.4584 | 15.9774 | 9.19107 | 7.52463 |
Dividends per Share - Common Stock Primary Issue | 1.16 | 1 | 0.85 | 0.74 | 0.66 |
Diluted Normalized EPS | 18.0254 | 21.9169 | 16.1875 | 8.85233 | 7.73455 |
Interest Expense (Income) - Net Operating | -17 | 1 | 2 | ||
Other Operating Expenses, Total | 59 | 47 | |||
Minority Interest | -10 | -3 | |||
Equity In Affiliates | -172 | -4 |
Jul 2023 | Apr 2023 | Dec 2022 | Oct 2022 | Jul 2022 | |
---|---|---|---|---|---|
Total revenue | 10687 | 10710 | 11450 | 10677 | 10970 |
Revenue | 10687 | 10710 | 11450 | 10677 | 10970 |
Cost of Revenue, Total | 6436 | 6570 | 6844 | 6375 | 6371 |
Gross Profit | 4251 | 4140 | 4606 | 4302 | 4599 |
Total Operating Expense | 9109 | 9147 | 9589 | 8967 | 8969 |
Selling/General/Admin. Expenses, Total | 2145 | 2119 | 2240 | 2208 | 2209 |
Research & Development | 345 | 346 | 391 | 351 | 365 |
Unusual Expense (Income) | 183 | 112 | 55 | 33 | 24 |
Operating Income | 1578 | 1563 | 1861 | 1710 | 2001 |
Interest Income (Expense), Net Non-Operating | -148 | -198 | -144 | -118 | -95 |
Other, Net | 0 | -2 | 60 | 9 | 11 |
Net Income Before Taxes | 1430 | 1363 | 1777 | 1601 | 1917 |
Net Income After Taxes | 1378 | 1317 | 1604 | 1570 | 1719 |
Net Income Before Extra. Items | 1361 | 1289 | 1576 | 1495 | 1664 |
Net Income | 1361 | 1289 | 1576 | 1495 | 1664 |
Income Available to Common Excl. Extra. Items | 1361 | 1289 | 1576 | 1495 | 1664 |
Income Available to Common Incl. Extra. Items | 1361 | 1289 | 1576 | 1495 | 1664 |
Diluted Net Income | 1361 | 1289 | 1576 | 1495 | 1664 |
Diluted Weighted Average Shares | 388 | 388 | 392 | 395 | 394 |
Diluted EPS Excluding Extraordinary Items | 3.50773 | 3.32216 | 4.02041 | 3.78481 | 4.22335 |
Dividends per Share - Common Stock Primary Issue | 0.35 | 0.3 | 0.3 | 0.3 | 0.3 |
Diluted Normalized EPS | 3.9672 | 3.67828 | 4.15857 | 3.92135 | 4.27797 |
Other Operating Expenses, Total | 59 | ||||
Minority Interest | -1 | -3 | 2 | -3 | -4 |
Equity In Affiliates | -16 | -25 | -30 | -72 | -51 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 25229 | 20113 | 21957 | 11893 | 10625 |
Cash and Short Term Investments | 8526 | 4477 | 10353 | 2436 | 2134 |
Cash & Equivalents | 8524 | 4477 | 10325 | 2399 | 2103 |
Short Term Investments | 2 | 28 | 37 | 31 | |
Total Receivables, Net | 9427 | 8945 | 6472 | 4952 | 4136 |
Accounts Receivable - Trade, Net | 9427 | 8945 | 6472 | 4952 | 4136 |
Total Inventory | 5634 | 5051 | 4029 | 3370 | 3005 |
Other Current Assets, Total | 1642 | 1640 | 1103 | 1135 | 1350 |
Total Assets | 97154 | 95123 | 69052 | 58381 | 56232 |
Property/Plant/Equipment, Total - Net | 10873 | 9864 | 6687 | 5448 | 4165 |
Property/Plant/Equipment, Total - Gross | 15862 | 14124 | 10352 | 8463 | 6820 |
Accumulated Depreciation, Total | -4989 | -4260 | -3665 | -3015 | -2655 |
Goodwill, Net | 41196 | 41924 | 26041 | 25714 | 25347 |
Intangibles, Net | 17442 | 20113 | 12685 | 14014 | 14978 |
Other Long Term Assets, Total | 2352 | 3087 | 1682 | 1312 | 1117 |
Total Current Liabilities | 17010 | 13436 | 10304 | 6197 | 6147 |
Accounts Payable | 3381 | 2867 | 2175 | 1920 | 1615 |
Accrued Expenses | 5433 | 5377 | 4098 | 2674 | 2436 |
Notes Payable/Short Term Debt | 310 | 2522 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 5269 | 15 | 2628 | 676 | 1271 |
Other Current Liabilities, Total | 2617 | 2655 | 1403 | 927 | 825 |
Total Liabilities | 53176 | 54330 | 34545 | 28706 | 28646 |
Total Long Term Debt | 28909 | 32333 | 19107 | 17076 | 17719 |
Long Term Debt | 28909 | 32333 | 19107 | 17076 | 17719 |
Deferred Income Tax | 2849 | 3837 | 1794 | 2192 | 2265 |
Other Liabilities, Total | 4238 | 4540 | 3340 | 3241 | 2515 |
Total Equity | 43978 | 40793 | 34507 | 29675 | 27586 |
Common Stock | 441 | 439 | 437 | 434 | 432 |
Additional Paid-In Capital | 16743 | 16174 | 15579 | 15064 | 14621 |
Retained Earnings (Accumulated Deficit) | 41910 | 35431 | 28116 | 22092 | 18696 |
Treasury Stock - Common | -12017 | -8922 | -6818 | -5236 | -3665 |
Unrealized Gain (Loss) | -33 | -35 | -91 | -71 | -52 |
Other Equity, Total | -3066 | -2294 | -2716 | -2608 | -2446 |
Total Liabilities & Shareholders’ Equity | 97154 | 95123 | 69052 | 58381 | 56232 |
Total Common Shares Outstanding | 390.511 | 394.435 | 396.671 | 398.74 | 402.122 |
Long Term Investments | 55 | 22 | |||
Minority Interest | 170 | 184 | |||
Note Receivable - Long Term | 7 |
Apr 2023 | Dec 2022 | Oct 2022 | Jul 2022 | Apr 2022 | |
---|---|---|---|---|---|
Total Current Assets | 20209 | 25229 | 19299 | 18100 | 18776 |
Cash and Short Term Investments | 3482 | 8526 | 2941 | 1893 | 2758 |
Cash & Equivalents | 3482 | 8524 | 2919 | 1888 | 2752 |
Short Term Investments | 2 | 22 | 5 | 6 | |
Total Receivables, Net | 9297 | 9427 | 8919 | 8892 | 8947 |
Accounts Receivable - Trade, Net | 9297 | 9427 | 8919 | 8892 | 8947 |
Total Inventory | 5664 | 5634 | 5722 | 5668 | 5483 |
Other Current Assets, Total | 1766 | 1642 | 1717 | 1647 | 1588 |
Total Assets | 94658 | 97154 | 90536 | 90579 | 92747 |
Property/Plant/Equipment, Total - Net | 9354 | 9280 | 8628 | 8529 | 8448 |
Goodwill, Net | 43140 | 41196 | 40488 | 41066 | 41721 |
Intangibles, Net | 17972 | 17442 | 17813 | 18578 | 19378 |
Other Long Term Assets, Total | 3975 | 4000 | 4299 | 4296 | 4413 |
Total Current Liabilities | 15884 | 17010 | 11118 | 10997 | 12070 |
Accounts Payable | 2798 | 3381 | 2471 | 2586 | 2667 |
Accrued Expenses | 4302 | 5433 | 5068 | 4678 | 4664 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 6122 | 5579 | 1010 | 1010 | 1866 |
Other Current Liabilities, Total | 2662 | 2617 | 2569 | 2723 | 2873 |
Total Liabilities | 52401 | 53176 | 46987 | 48286 | 51791 |
Total Long Term Debt | 29135 | 28909 | 28150 | 29250 | 30095 |
Long Term Debt | 29135 | 28909 | 28150 | 29250 | 30095 |
Deferred Income Tax | 2976 | 2849 | 3140 | 3327 | 3493 |
Other Liabilities, Total | 4230 | 4238 | 4401 | 4534 | 5958 |
Total Equity | 42257 | 43978 | 43549 | 42293 | 40956 |
Common Stock | 441 | 441 | 440 | 440 | 440 |
Additional Paid-In Capital | 16889 | 16743 | 16596 | 16467 | 16292 |
Retained Earnings (Accumulated Deficit) | 43064 | 41910 | 40452 | 39074 | 37528 |
Treasury Stock - Common | -15083 | -12017 | -11011 | -10964 | -10961 |
Unrealized Gain (Loss) | -30 | -33 | -33 | -34 | -34 |
Other Equity, Total | -3024 | -3066 | -2895 | -2690 | -2309 |
Total Liabilities & Shareholders’ Equity | 94658 | 97154 | 90536 | 90579 | 92747 |
Total Common Shares Outstanding | 385.721 | 390.511 | 392.196 | 391.789 | 391.439 |
Property/Plant/Equipment, Total - Gross | |||||
Accumulated Depreciation, Total | |||||
Minority Interest | 176 | 170 | 178 | 178 | 175 |
Note Receivable - Long Term | 8 | 7 | 9 | 10 | 11 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 6960 | 7728 | 6375 | 3696 | 2938 |
Cash From Operating Activities | 9154 | 9312 | 8289 | 4973 | 4543 |
Cash From Operating Activities | 986 | 831 | 658 | 564 | 2267 |
Deferred Taxes | -995 | -647 | -552 | -302 | -379 |
Non-Cash Items | 857 | 1187 | 536 | -33 | 287 |
Changes in Working Capital | -1049 | -1548 | -395 | -665 | -570 |
Cash From Investing Activities | -2159 | -21932 | -1510 | -1487 | -1253 |
Capital Expenditures | -2243 | -2523 | -1474 | -926 | -758 |
Other Investing Cash Flow Items, Total | 84 | -19409 | -36 | -561 | -495 |
Cash From Financing Activities | -2810 | 6581 | 959 | -3118 | -2237 |
Financing Cash Flow Items | -9 | -91 | -147 | -69 | -51 |
Total Cash Dividends Paid | -455 | -395 | -337 | -297 | -266 |
Issuance (Retirement) of Stock, Net | -3000 | -1844 | -1304 | -1347 | -364 |
Issuance (Retirement) of Debt, Net | 654 | 8911 | 2747 | -1405 | -1556 |
Foreign Exchange Effects | -139 | 194 | 176 | -63 | -297 |
Net Change in Cash | 4046 | -5845 | 7914 | 305 | 756 |
Cash Taxes Paid | 1234 | 2182 | 1324 | 896 | 591 |
Cash Interest Paid | 667 | 555 | 471 | 790 | 687 |
Amortization | 2395 | 1761 | 1667 | 1713 |
Apr 2023 | Dec 2022 | Oct 2022 | Jul 2022 | Apr 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1292 | 6960 | 5386 | 3888 | 2220 |
Cash From Operating Activities | 729 | 9154 | 5667 | 3730 | 2202 |
Cash From Operating Activities | 253 | 986 | 730 | 486 | 250 |
Amortization | 606 | 2395 | 1803 | 1209 | 609 |
Deferred Taxes | -146 | -995 | -862 | -601 | -339 |
Non-Cash Items | 257 | 857 | 701 | 472 | 337 |
Changes in Working Capital | -1533 | -1049 | -2091 | -1724 | -875 |
Cash From Investing Activities | -3142 | -2159 | -1634 | -1089 | -670 |
Capital Expenditures | -458 | -2243 | -1693 | -1146 | -640 |
Other Investing Cash Flow Items, Total | -2684 | 84 | 59 | 57 | -30 |
Cash From Financing Activities | -2593 | -2810 | -5201 | -5050 | -3145 |
Financing Cash Flow Items | 20 | -9 | -86 | -48 | -36 |
Total Cash Dividends Paid | -117 | -455 | -338 | -220 | -103 |
Issuance (Retirement) of Stock, Net | -3000 | -3000 | -1943 | -1949 | -1998 |
Issuance (Retirement) of Debt, Net | 504 | 654 | -2834 | -2833 | -1008 |
Foreign Exchange Effects | -31 | -139 | -389 | -177 | -99 |
Net Change in Cash | -5037 | 4046 | -1557 | -2586 | -1712 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.3978 | 32411301 | 3067 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.7696 | 18408301 | -388612 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.1759 | 16116956 | 55458 | 2023-06-30 | LOW |
Capital World Investors | Investment Advisor | 3.3362 | 12876098 | -48366 | 2023-06-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 2.2469 | 8672091 | -2077992 | 2023-06-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.2212 | 8572754 | 547312 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8082 | 6978869 | -6715 | 2023-06-30 | LOW |
MFS Investment Management | Investment Advisor/Hedge Fund | 1.6887 | 6517361 | -1270699 | 2023-06-30 | LOW |
Capital Research Global Investors | Investment Advisor | 1.5783 | 6091325 | 157512 | 2023-06-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.4612 | 5639611 | 219567 | 2022-12-31 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 1.1087 | 4278887 | 209573 | 2023-06-30 | LOW |
Morgan Stanley Investment Management Ltd. (UK) | Investment Advisor | 1.0313 | 3980403 | 378915 | 2023-06-30 | LOW |
TCI Fund Management Limited | Hedge Fund | 0.8222 | 3173182 | 2339032 | 2023-06-30 | LOW |
Arthur M. Cohen & Associates, LLC | Investment Advisor | 0.8094 | 3124051 | 3113975 | 2023-06-30 | MED |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.8035 | 3100948 | -193634 | 2023-06-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 0.7975 | 3078107 | -486002 | 2023-06-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.7742 | 2987984 | -243076 | 2023-06-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 0.7271 | 2806223 | -83893 | 2023-06-30 | LOW |
BofA Global Research (US) | Research Firm | 0.7041 | 2717630 | -367618 | 2023-06-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.6763 | 2610108 | 50802 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Thermo Fisher Company profile
Thermo Fisher Scientific Inc. (TMO) is a supplier of scientific laboratory products, instruments, software and other tools. The company was formed in a tax-free stock-for-stock merger of Thermo Electron Corporation with Fisher Scientific International Inc. in 2006.
The company provides services through various brands including Thermo Fishers, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Thermo Fisher works on accelerating life sciences research by solving complex analytical challenges. Its products aim to increase productivity in laboratories and improve patient health through diagnostics and therapy development.
The four segments that Thermo Fisher Scientific caters to are industrial and applied research, diagnostics and healthcare, academic and government research, and pharmaceuticals and biotechnology.
As of June 2022, Thermo Fisher has developed Orbitrap Exploris MX mass spectrometer, cell therapy workflow solutions, Oncomine Dx Target Test and several other solutions that aim to make the diagnosis of infections and diseases easier and enable production of drugs and vaccines.
Thermo Fisher Scientific Inc. stock is trading on the New York Stock Exchange (NYSE) under the ticker symbol TMO. You can follow live TMO stock movement and price history, and stay on top of the latest TMO share value at Capital.com.
Industry: | Advanced Medical Equipment & Technology (NEC) |
168 Third Avenue
WALTHAM
MASSACHUSETTS 02451
US
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com